Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Physiomics Share Price
  4. Physiomics Share Regulatory News
  5. Share Price Movement

Pin to quick picksPhysiomics Regulatory News (PYC)

Physiomics Information

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.625    -0.025 (-3.85%)
Bid:
0.60
Ask:
0.65
Spread: 0.05 (8.333%)
Market Cap: £2.83m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Share Price Movement

29 May 2012 12:37

RNS Number : 3302E
Physiomics PLC
29 May 2012
 



Physiomics plc

 

(the "Company" or "Physiomics")

 

Share Price Movement

 

Following the recent movement in its share price today, the Company notes that ValiRx plc has today announced some positive results relating to their VAL 201 compound.

 

As announced on 13 September 2011, Physiomics has a revenue sharing deal in place with ValiRx in respect of VAL 201.

 

Today's announcement from ValiRx sets out the results from an independent pre-clinical study into VAL201 and confirms that ValiRx has started the regulatory filing process towards a phase I clinical trial application for VAL201 with the relevant regulatory bodies in the UK and Europe.

 

Enquiries:

Physiomics plc

Dr Mark Chadwick, CEO

+44 (0)1865 784 980

WH Ireland Limited (broker/nomad)

Katy Mitchell

+44 (0) 161 832 2174

Media enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFVLERIAFIF
12345678910
Date   Source Headline
29th Apr 20154:27 pmRNSHolding(s) in Company
22nd Apr 20157:00 amRNSVirtual Tumour platform - AACR Annual Meeting 2015
26th Mar 20157:00 amRNSIssue of Options
17th Mar 20157:00 amRNSHalf Yearly Report
12th Mar 20157:00 amRNSIssue of Equity
6th Mar 20151:40 pmRNSHolding(s) in Company
4th Mar 201511:56 amRNSHolding(s) in Company
3rd Mar 201512:57 pmRNSFirst contract for clinical version of Virtu
20th Feb 201512:34 pmRNSHolding(s) in Company
2nd Feb 20157:00 amRNSTermination of Equity Swap Agreement
15th Dec 20141:08 pmRNSResult of AGM
12th Nov 201410:24 amRNSFinal Results
4th Nov 20147:00 amRNSDisclosure of Large Pharma partner Merck & Co
27th Oct 201410:07 amRNSProject extension with global pharma company
13th Oct 20144:43 pmRNSHolding(s) in Company
7th Oct 20149:35 amRNSCardiotox Platform Launch
29th Aug 20142:47 pmRNSHolding(s) in Company
14th Aug 20141:10 pmRNSNew deal with global pharma
24th Jul 201412:59 pmRNSIssue of Equity
26th Jun 20147:57 amRNSHolding(s) in Company
12th Jun 20147:00 amRNSAnticipated new collaboration with Diatech
20th May 20149:47 amRNSHolding(s) in Company
10th Apr 20147:00 amRNSSecond validation of Virtual Tumour Clinical
14th Feb 20147:00 amRNSHalf Yearly Report
30th Jan 20144:41 pmRNSIssue of Equity - Replacement
30th Jan 20143:02 pmRNSIssue of Equity
16th Jan 20147:20 amRNSDundee University Collaboration
17th Dec 20132:07 pmRNSResult of AGM
4th Dec 201310:47 amRNSVirtual Tumour Proposal
28th Nov 20131:24 pmRNSDrugCARD launch
15th Nov 20137:00 amRNSFinal Results
11th Nov 20137:00 amRNSUniversity of Oxford Collaboration
4th Nov 20137:00 amRNSUpdate on the Virtual Tumour Clinical platform
10th Oct 201310:30 amRNSDrawdown pursuant to SEDA Arrngmnt/Issue of Equity
7th Oct 20138:32 amRNSPhysiomics gains new speciality pharma customer
1st Oct 201311:49 amRNSPhysiomics gains first large pharma customer
16th Sep 20137:00 amRNSPhysiomics to present cardiac toxicity platform
26th Jul 20131:30 pmRNSIssue of Equity
1st Jul 20137:00 amRNSAdditional SEDA Drawdown
24th Jun 20137:00 amRNSWins Poster Award
20th Jun 20134:28 pmRNSAward of Grant
11th Jun 20137:00 amRNSPopulation Approach Group Europe
6th Jun 20137:00 amRNSVirtual Tumour Clinical Contract
8th Apr 20138:03 amRNSPhysiomics to present new developments
25th Mar 20137:00 amRNSPhysiomics to provide cardiac toxicity modelling
18th Mar 20137:00 amRNSNew clinical PK/PD modelling service
13th Feb 201311:10 amRNSIssue of Options
11th Feb 20133:23 pmRNSDirector Declaration
8th Feb 20137:00 amRNSHalf Yearly Report
22nd Jan 20137:00 amRNSSEDA Arrangement
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
SEQI
Sequoia Economic Infrastructure Fund
LSE
0.99%
PCFT
Polar Cap Gbl
LSE
0.67%
JNY
JNY.L
LSE
0.00%
ASCI
ASCI.L
LSE
0.00%
AAS
Aberdeen Asia
LSE
-0.45%
Trending
GGP
Greatland Resources
LSE
-0.42%
ARS
Asiamet Resources Limited
LSE
1.79%
GKP
Gulf Keystone Petroleum
LSE
6.92%
PREM
Premier African Minerals
LSE
-16.00%
MPL
Mercantile Ports & Logistics
LSE
3.33%